Dynamic market changes demand new approaches to long and short-term financial strategies, fresh perspective on licensing and collaborations and risk management strategies to sustain both early and established life sciences companies.
Foley & Lardner along with our event partners, BioMed Realty Trust and Berkley Life Sciences present, “Winning Genes: How to Create, Grow and Sustain a Successful Life Sciences Company”. During this half-day conference, financial advisors, industry leaders and legal counsel will provide insight on critical business and legal issues during the following interactive panels:
Special Keynote Presentation
We are pleased to host, Dr. Robert Langer, Institute Professor at MIT, as our keynote speaker. Dr. Langer will enlighten attendees by providing his perspective on how biotechnology entrepreneurs can succeed in today's post-recession market and share a forward looking perspective on the where the industry is heading as it relates to technology innovation and venture capitalism.
For additional information please contact Meg Ryan at firstname.lastname@example.org.
In today’s market, life science companies large and small are adjusting their collaboration and licensing strategies to account for a more robust economic outlook. These strategies have created new options for smaller companies while larger companies are engaging in partnerships that may potentially minimize their risks. During this interactive panel speakers will cover the following aspects of short and long term deal making:
Coming off of a challenging economic recession, exit strategies in the life sciences industry are changing. Still adapting to the short term effects of the recession, new approaches to exits are being established which will have a long term impact on the industry. A panel of venture capitalists, investment bankers and entrepreneurs will discuss short and long term strategies for taking a life sciences company to the next level.
The cost of research and development in the life sciences industry continues to rise along with the financial liability risks a company takes on as it commercializes products. These R&D and regulatory challenges create a perfect storm, as a result, the development of a risk management plan is more important than ever. For corporate executives and investors alike, when it comes to product development it is never too early to have your risk management plan in place.
During this interactive panel, speakers will discuss the following:
For companies entering biotech and pharmaceutical markets in Europe and China, regulatory and IP challenges can easily impact business endeavors and halt your expansion plans. Proper planning and knowledge on common pitfalls can make the difference between a successful foreign venture and a failure.
This session will explore the following topics: